These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2775324)

  • 1. Comment on the article by van Kerckhove et al.
    Mueller MN
    Arthritis Rheum; 1989 Sep; 32(9):1185-6. PubMed ID: 2775324
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis.
    Giannini EH; Cassidy JT; Brewer EJ; Shaikov A; Maximov A; Kuzmina N
    Semin Arthritis Rheum; 1993 Aug; 23(1):34-46. PubMed ID: 8235664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial.
    Brewer EJ; Giannini EH; Kuzmina N; Alekseev L
    N Engl J Med; 1986 May; 314(20):1269-76. PubMed ID: 3517643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis.
    Bunch TW; O'Duffy JD; Tompkins RB; O'Fallon WM
    Arthritis Rheum; 1984 Mar; 27(3):267-76. PubMed ID: 6367750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis.
    Giannini EH; Brewer EJ; Kuzmina N; Alekseev L; Shokh BP
    Arthritis Rheum; 1988 Jan; 31(1):15-20. PubMed ID: 3257872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients.
    van Kerckhove C; Giannini EH; Lovell DJ
    Arthritis Rheum; 1988 Oct; 31(10):1252-8. PubMed ID: 3178907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-loading with hydroxychloroquine in rheumatoid arthritis: comment on the article by Furst et al.
    Handler RP
    Arthritis Rheum; 1999 Jul; 42(7):1556. PubMed ID: 10403290
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of juvenile rheumatoid arthritis with oral type II collagen: comment on the article by Barnett et al.
    Malleson P
    Arthritis Rheum; 1997 Feb; 40(2):392-3. PubMed ID: 9041956
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum histidine in rheumatoid arthritis: changes induced by antirheumatic drug therapy.
    Pickup ME; Dixon JS; Lowe JR; Wright V
    J Rheumatol; 1980; 7(1):71-6. PubMed ID: 7354471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy for childhood rheumatic diseases. Have we been doing enough?
    Schaller JG
    Arthritis Rheum; 1993 Jan; 36(1):65-70. PubMed ID: 8424838
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of D-penicillamine in juvenile chronic arthritis. A double-blind, multicenter study.
    Prieur AM; Piussan C; Manigne P; Bordigoni P; Griscelli C
    Arthritis Rheum; 1985 Apr; 28(4):376-82. PubMed ID: 3885958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological management of juvenile rheumatoid arthritis.
    Rose CD; Doughty RA
    Drugs; 1992 Jun; 43(6):849-63. PubMed ID: 1379157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical management of the juvenile idiopathic arthritis patient with multiple joint involvement.
    Abdel MP; Figgie MP
    Orthop Clin North Am; 2014 Oct; 45(4):435-42. PubMed ID: 25199416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al.
    Huppertz HI
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1354-5; author reply 1355-6. PubMed ID: 21671416
    [No Abstract]   [Full Text] [Related]  

  • 15. Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al.
    Kimura Y; DeWitt EM; Beukelman T; Stoll ML; Nigrovic PA; Onel K; Prahalad S; Angeles-Han S; Schneider R;
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1430-1. PubMed ID: 24719268
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evaluation of the usefulness of delayed-action preparations in the treatment of rheumatoid polyarthritis by analyzing the therapeutic maintenance dose].
    Dougados M; Nguyen M; Duchesne L; Benjelloun M; Amor B
    Rev Rhum Mal Osteoartic; 1989 Jan; 56(1):89-92. PubMed ID: 2727586
    [No Abstract]   [Full Text] [Related]  

  • 17. D-penicillamine-induced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. Report of a case and review of the literature.
    Sahn EE; Maize JC; Garen PD; Mullins SC; Silver RM
    J Am Acad Dermatol; 1989 May; 20(5 Pt 2):979-88. PubMed ID: 2523911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of penicillamine treatment on immune complexes in two cases of seropositive juvenile rheumatoid arthritis.
    Bresnihan FP; Ansell BM
    Ann Rheum Dis; 1975 Oct; 35(5):463-5. PubMed ID: 1086656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-related membranous nephropathy in juvenile idiopathic arthritis with Turner syndrome.
    Suzuki K; Tanaka H; Ito E; Waga S
    Pediatr Int; 2004 Jun; 46(3):377-9. PubMed ID: 15151564
    [No Abstract]   [Full Text] [Related]  

  • 20. Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et Al.
    Brunner H; Lomax KG; Levy S
    Arthritis Rheumatol; 2015 Mar; 67(3):857-8. PubMed ID: 25512026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.